© 2021 MJH Life Sciences and Gene Therapy Live. All rights reserved.
© 2021 MJH Life Sciences™ and Gene Therapy Live. All rights reserved.
Bayer provided an update on trials currently underway for the treatment of PD by its subsidiaries.
Locanabio CEO James Burns, PhD, discusses the firm's targeted approach to treating genetic disorders of the central nervous system and the eye.
Asklepios BioPharmaceuticals noted that it plans to initiate dosing for the LION-101 phase 1/2 clinical trial in the first half of 2022.